Association of serum phospholipid PUFAs with cardiometabolic risk: Beneficial effect of DHA on the suppression of vascular proliferation/inflammation

Juhyun Song, Nayeon Kwon, Mi Hyang Lee, Young Guk Ko, Jong Ho Lee, Oh Yoen Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: Blood or dietary polyunsaturated fatty acids (PUFAs), particularly ω3-PUFAs were known for cardiovascular protective effect. However, the results are still controversial. We aimed to investigate the association of serum phospholipid PUFAs with cardiometabolic risk through cross-sectional/experimental studies. Design/methods: Serum phospholipid FA compositions and cardiometabolic risk parameters were measured in controls [healthy: n. = 987, metabolic syndrome (MetS): n. = 214] and CAD patients (CAD-only: n. = 152, CAD. +. MetS: n. = 56). Experimental assays were performed in vascular smooth muscle cells (VSMCs). Results: Major cardiometabolic risk markers, i.e. insulin resistance, hs-C-reactive proteins, and malondialdehyde were higher, and adiponectin and LDL particle size were lower in CAD patients, particularly those with MetS than in healthy controls. Serum linoleic acid (LA, C18:2ω-6) was lowest and dihomo-γ-linolenic acids (DGLAs, C20:3ω-6) were highest in CAD patients with MetS among the 4 groups. Docosahexaenoic acid (DHA, C22:6ω-3) was lower and arachidonic acid (AA, C20:4ω-6) and ω6/ω3-PUFAs were higher in CAD patients than in controls. ω3-PUFAs were significantly lower in CAD patients, particularly those with MetS than in healthy controls. Multiple regression analysis revealed that AA and DHA among serum FAs were mainly associated with the cardiometabolic risk (β'-coefficients for AA:0.336; DHA: -. 0.296) together with age, MetS factors, LA, DGLA and gender (r. = 0.529, p. <. 0.001). Under LPS-induced stress condition, LA and DHA significantly suppressed VSMC proliferation. DHA also up-regulated the phosphorylation of p38 and ERK, and dramatically inhibited nuclear translocation of NF-κB-p65 in VSMCs. Conclusion: AA and DHA were mainly associated with cardiometabolic risk. Particularly, DHA may be effective on suppression of vascular proliferation and inflammation.

Original languageEnglish
Pages (from-to)361-368
Number of pages8
JournalClinical Biochemistry
Volume47
Issue number6
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Unsaturated Fatty Acids
Blood Vessels
Phospholipids
Computer aided design
Inflammation
Serum
Vascular Smooth Muscle
Smooth Muscle Myocytes
Muscle
Linolenic Acids
Docosahexaenoic Acids
Adiponectin
Linoleic Acid
Phosphorylation
Malondialdehyde
Particle Size
Arachidonic Acid
C-Reactive Protein
Cell proliferation
Insulin Resistance

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

@article{3070b7cc8fe649358356196459375b58,
title = "Association of serum phospholipid PUFAs with cardiometabolic risk: Beneficial effect of DHA on the suppression of vascular proliferation/inflammation",
abstract = "Objectives: Blood or dietary polyunsaturated fatty acids (PUFAs), particularly ω3-PUFAs were known for cardiovascular protective effect. However, the results are still controversial. We aimed to investigate the association of serum phospholipid PUFAs with cardiometabolic risk through cross-sectional/experimental studies. Design/methods: Serum phospholipid FA compositions and cardiometabolic risk parameters were measured in controls [healthy: n. = 987, metabolic syndrome (MetS): n. = 214] and CAD patients (CAD-only: n. = 152, CAD. +. MetS: n. = 56). Experimental assays were performed in vascular smooth muscle cells (VSMCs). Results: Major cardiometabolic risk markers, i.e. insulin resistance, hs-C-reactive proteins, and malondialdehyde were higher, and adiponectin and LDL particle size were lower in CAD patients, particularly those with MetS than in healthy controls. Serum linoleic acid (LA, C18:2ω-6) was lowest and dihomo-γ-linolenic acids (DGLAs, C20:3ω-6) were highest in CAD patients with MetS among the 4 groups. Docosahexaenoic acid (DHA, C22:6ω-3) was lower and arachidonic acid (AA, C20:4ω-6) and ω6/ω3-PUFAs were higher in CAD patients than in controls. ω3-PUFAs were significantly lower in CAD patients, particularly those with MetS than in healthy controls. Multiple regression analysis revealed that AA and DHA among serum FAs were mainly associated with the cardiometabolic risk (β'-coefficients for AA:0.336; DHA: -. 0.296) together with age, MetS factors, LA, DGLA and gender (r. = 0.529, p. <. 0.001). Under LPS-induced stress condition, LA and DHA significantly suppressed VSMC proliferation. DHA also up-regulated the phosphorylation of p38 and ERK, and dramatically inhibited nuclear translocation of NF-κB-p65 in VSMCs. Conclusion: AA and DHA were mainly associated with cardiometabolic risk. Particularly, DHA may be effective on suppression of vascular proliferation and inflammation.",
author = "Juhyun Song and Nayeon Kwon and Lee, {Mi Hyang} and Ko, {Young Guk} and Lee, {Jong Ho} and Kim, {Oh Yoen}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.clinbiochem.2014.01.005",
language = "English",
volume = "47",
pages = "361--368",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "6",

}

Association of serum phospholipid PUFAs with cardiometabolic risk : Beneficial effect of DHA on the suppression of vascular proliferation/inflammation. / Song, Juhyun; Kwon, Nayeon; Lee, Mi Hyang; Ko, Young Guk; Lee, Jong Ho; Kim, Oh Yoen.

In: Clinical Biochemistry, Vol. 47, No. 6, 01.01.2014, p. 361-368.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association of serum phospholipid PUFAs with cardiometabolic risk

T2 - Beneficial effect of DHA on the suppression of vascular proliferation/inflammation

AU - Song, Juhyun

AU - Kwon, Nayeon

AU - Lee, Mi Hyang

AU - Ko, Young Guk

AU - Lee, Jong Ho

AU - Kim, Oh Yoen

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives: Blood or dietary polyunsaturated fatty acids (PUFAs), particularly ω3-PUFAs were known for cardiovascular protective effect. However, the results are still controversial. We aimed to investigate the association of serum phospholipid PUFAs with cardiometabolic risk through cross-sectional/experimental studies. Design/methods: Serum phospholipid FA compositions and cardiometabolic risk parameters were measured in controls [healthy: n. = 987, metabolic syndrome (MetS): n. = 214] and CAD patients (CAD-only: n. = 152, CAD. +. MetS: n. = 56). Experimental assays were performed in vascular smooth muscle cells (VSMCs). Results: Major cardiometabolic risk markers, i.e. insulin resistance, hs-C-reactive proteins, and malondialdehyde were higher, and adiponectin and LDL particle size were lower in CAD patients, particularly those with MetS than in healthy controls. Serum linoleic acid (LA, C18:2ω-6) was lowest and dihomo-γ-linolenic acids (DGLAs, C20:3ω-6) were highest in CAD patients with MetS among the 4 groups. Docosahexaenoic acid (DHA, C22:6ω-3) was lower and arachidonic acid (AA, C20:4ω-6) and ω6/ω3-PUFAs were higher in CAD patients than in controls. ω3-PUFAs were significantly lower in CAD patients, particularly those with MetS than in healthy controls. Multiple regression analysis revealed that AA and DHA among serum FAs were mainly associated with the cardiometabolic risk (β'-coefficients for AA:0.336; DHA: -. 0.296) together with age, MetS factors, LA, DGLA and gender (r. = 0.529, p. <. 0.001). Under LPS-induced stress condition, LA and DHA significantly suppressed VSMC proliferation. DHA also up-regulated the phosphorylation of p38 and ERK, and dramatically inhibited nuclear translocation of NF-κB-p65 in VSMCs. Conclusion: AA and DHA were mainly associated with cardiometabolic risk. Particularly, DHA may be effective on suppression of vascular proliferation and inflammation.

AB - Objectives: Blood or dietary polyunsaturated fatty acids (PUFAs), particularly ω3-PUFAs were known for cardiovascular protective effect. However, the results are still controversial. We aimed to investigate the association of serum phospholipid PUFAs with cardiometabolic risk through cross-sectional/experimental studies. Design/methods: Serum phospholipid FA compositions and cardiometabolic risk parameters were measured in controls [healthy: n. = 987, metabolic syndrome (MetS): n. = 214] and CAD patients (CAD-only: n. = 152, CAD. +. MetS: n. = 56). Experimental assays were performed in vascular smooth muscle cells (VSMCs). Results: Major cardiometabolic risk markers, i.e. insulin resistance, hs-C-reactive proteins, and malondialdehyde were higher, and adiponectin and LDL particle size were lower in CAD patients, particularly those with MetS than in healthy controls. Serum linoleic acid (LA, C18:2ω-6) was lowest and dihomo-γ-linolenic acids (DGLAs, C20:3ω-6) were highest in CAD patients with MetS among the 4 groups. Docosahexaenoic acid (DHA, C22:6ω-3) was lower and arachidonic acid (AA, C20:4ω-6) and ω6/ω3-PUFAs were higher in CAD patients than in controls. ω3-PUFAs were significantly lower in CAD patients, particularly those with MetS than in healthy controls. Multiple regression analysis revealed that AA and DHA among serum FAs were mainly associated with the cardiometabolic risk (β'-coefficients for AA:0.336; DHA: -. 0.296) together with age, MetS factors, LA, DGLA and gender (r. = 0.529, p. <. 0.001). Under LPS-induced stress condition, LA and DHA significantly suppressed VSMC proliferation. DHA also up-regulated the phosphorylation of p38 and ERK, and dramatically inhibited nuclear translocation of NF-κB-p65 in VSMCs. Conclusion: AA and DHA were mainly associated with cardiometabolic risk. Particularly, DHA may be effective on suppression of vascular proliferation and inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84897112127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897112127&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2014.01.005

DO - 10.1016/j.clinbiochem.2014.01.005

M3 - Article

C2 - 24457065

AN - SCOPUS:84897112127

VL - 47

SP - 361

EP - 368

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 6

ER -